ArticleProceedings of the National Academy of Sciences of the United States of America2012
Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 161 citations in OpenAlex.
- High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women.Frontiers in endocrinology · 2021Trial
- Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Trial
- FSH suppression does not affect bone turnover in eugonadal men.The Journal of clinical endocrinology and metabolism · 2014Trial
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- The extragonadal biology of gonadotropin hormones: should we rename these?Endocrine connections · 2026Article
- From farm to lab: gene-edited sheep transforming bone research.JBMR plus · 2026Review
- Neuroendocrine and neural control of bone mass in health and disease.The Journal of clinical investigation · 2026Review
- Fshr gene depletion prevents recognition memory loss, fat accrual and bone loss in Alzheimer's mice.Molecular psychiatry · 2026Article
- Induction of puberty in hypogonadal forms of primary amenorrhoea: current evidence and future perspectives.Endocrine connections · 2026Review
- Follicle-Stimulating Hormone in Peripheral Metabolism: Novel Insights into Growth Regulation and Potential Applications in Boar Production.Animals : an open access journal from MDPI · 2026Review
- C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis.Bone research · 2026Article
- FSH Signaling in Osteoporosis and Alzheimer's Disease.Current osteoporosis reports · 2026Review
- Targeting FSH for osteoporosis, obesity, and Alzheimer's disease.Trends in molecular medicine · 2025Review
- The Effects of FSH Versus GnRH Vaccination on Growth Performance and Meat Quality of Surgically Castrated Male Growing-Finishing Pigs.Animals : an open access journal from MDPI · 2025Article
- Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models.The Journal of clinical investigation · 2025Article
- Higher FSH Level Is Associated With Increased Risk of Incident Hip Fracture in Older Adults, Independent of Sex Hormones.The Journal of clinical endocrinology and metabolism · 2025Article
- Gene-dose-dependent reduction of Fshr expression improves spatial memory deficits in Alzheimer's mice.Molecular psychiatry · 2025Article
- Follicle-stimulating hormone promotes EndMT in endothelial cells by upregulating ALKBH5 expression.Cellular & molecular biology letters · 2025Article
- Review
- Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
Low estrogen levels undoubtedly underlie menopausal bone thinning. However, rapid and profuse bone loss begins 3 y before the last menstrual period, when serum estrogen is relatively normal. We have shown that the pituitary hormone FSH, the levels of which are high during late perimenopause, directly stimulates bone resorption by osteoclasts. Here, we generated and characterized a polyclonal antibody to a 13-amino-acid-long peptide sequence within the receptor-binding domain of the FSH β-subunit. We show that the FSH antibody binds FSH specifically and blocks its action on osteoclast formation in vitro. When injected into ovariectomized mice, the FSH antibody attenuates bone loss significantly not only by inhibiting bone resorption, but also by stimulating bone formation, a yet uncharacterized action of FSH that we report herein. Mesenchymal cells isolated from mice treated with the FSH antibody show greater osteoblast precursor colony counts, similarly to mesenchymal cells isolated from FSH receptor (FSHR)(-/-) mice. This suggests that FSH negatively regulates osteoblast number. We confirm that this action is mediated by signaling-efficient FSHRs present on mesenchymal stem cells. Overall, the data prompt the future development of an FSH-blocking agent as a means of uncoupling bone formation and bone resorption to a therapeutic advantage in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.